Study guide
7.2 Container Labeling, MedGuides & Patient Package Inserts
Massachusetts MPJE Pharmacy Jurisprudence Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Federal Drug Law & Regulatory Foundations
1.1 Federal Acts & Agencies 1.2 Drug Supply Chain Security & Adulteration/Misbranding 1.3 Poison Prevention & Special Packaging Standards
2 Chapter 2: Federal Controlled Substances Act (CSA) Governance
2.1 CSA Scheduling, Registration & Ordering 2.2 Controlled Substance Inventory, Theft & Disposal 2.3 Corresponding Responsibility & DEA Red Flags
3 Chapter 3: Massachusetts Board Authority, Licensure & Continuing Education
3.1 Board of Registration in Pharmacy: Structure & Enforcement 3.2 Pharmacist Licensure, Reciprocity & Renewal 3.3 Continuing Education Requirements
4 Chapter 4: Massachusetts Pharmacy Personnel & Supervision
4.1 Pharmacy Interns: Licensure, Hours & Preceptors 4.2 Pharmacy Technician Licensure Tiers & Scope 4.3 Supervisory Ratios & Direct Supervision 4.4 Manager of Record: Duties, Appointment & Reporting
5 Chapter 5: Prescription Validity, Prescriber Authority & Opioid Limits
5.1 Elements of a Valid Massachusetts Prescription 5.2 Prescriber Authority & the Massachusetts Controlled Substances Registration 5.3 The Massachusetts Electronic Prescribing Mandate 5.4 M.G.L. c. 94C, Massachusetts Schedules & Prescription Validity Windows 5.5 Opioid Prescribing Limits & Partial Fill Rights
6 Chapter 6: Refills, Transfers, Recordkeeping & Emergency Dispensing
6.1 Refill Limits, Sequential Schedule II Prescriptions & Partial Fills 6.2 Prescription Transfers & Pharmacy Recordkeeping 6.3 Out-of-State Prescriptions 6.4 Emergency Dispensing: Oral Schedule II Orders & Schedule VI Emergency Supplies
7 Chapter 7: Product Selection, Labeling & Patient Care Standards
7.1 Mandatory Interchange & the Massachusetts List of Interchangeable Drug Products 7.2 Container Labeling, MedGuides & Patient Package Inserts 7.3 Patient Counseling, Profiles & Drug Utilization Review 7.4 Pharmacist Administration of Drugs & Vaccines 7.5 Returning, Reusing & Disposing of Dispensed Drugs
8 Chapter 8: MassPAT, Nonprescription Products, Public Health & Privacy
8.1 MassPAT: Prescription Monitoring Program Query & Reporting 8.2 Naloxone, Syringes & Standing Orders 8.3 Patient Privacy (HIPAA) & Massachusetts Privacy Rules 8.4 Nonprescription, Behind-the-Counter & Restricted OTC Products
9 Chapter 9: Pharmacy Facilities, Security, Automation & Quality
9.1 Pharmacy Licensure, Facilities & Required References 9.2 Continuous Quality Improvement & Quality Related Events 9.3 Pharmacy Practice Automation & Automated Dispensing Devices 9.4 Security, Delivery, Central Fill & Non-Resident Practice
10 Chapter 10: Compounding, Hazardous Drugs & Expanded Pharmacist Practice
10.1 Non-Sterile Compounding: USP <795> & the Massachusetts Overlay 10.2 Sterile Compounding: USP <797> & the Massachusetts Overlay 10.3 Hazardous Drugs & USP <800> 10.4 Collaborative Drug Therapy Management
11 Chapter 11: The MPJE Blueprint, Delivery & Scoring
11.1 How the MPJE Is Built, Delivered and Scored
7.2 Container Labeling, MedGuides & Patient Package Inserts
Key Takeaways Explain This Topic AI
Prescription labelling in Massachusetts is governed by M.G.L. c. 94C, § 21 together with the Board's professional practice standards in 247 CMR 9.00.
Where an interchange has been made, M.G.L. c. 112, § 12D additionally requires the label to show 'Interchange (name of exact drug product dispensed)'.
Under 21 CFR 290.5 the federal transfer warning is required on container labels for Schedules II, III and IV only — not Schedule V and not Schedule VI.
FDA Medication Guides must be provided with every outpatient fill of a covered drug, new prescriptions and refills alike, under 21 CFR Part 208.
Patient Package Inserts for oral contraceptives and estrogen products go out with every outpatient dispensing, and in institutional settings before the first dose and every 30 days thereafter.
Last updated: August 2026
7.2 Container Labeling & Patient Package Inserts
MPJE Core Concept: Dispensing a prescription medication in Massachusetts without a legally compliant container label or without mandatory patient risk disclosures (MedGuides and PPIs) constitutes statutory misbranding under federal law and violates M.G.L. c. 94C § 21 and 247 CMR 9.00 .
Pharmacy practitioners must ensure that every prescription package leaving the pharmacy complies with state container labeling requirements and federal mandates governing written patient drug information.
Massachusetts Prescription Container Label Requirements
Prescription labelling is governed by M.G.L. c. 94C, § 21 together with the Board's professional practice standards in 247 CMR 9.00 . Whenever a pharmacy dispenses a prescription medication to an outpatient, the container must bear a securely affixed label. The required content is:
Pharmacy Name and Address: Full registered trade name and physical address of the dispensing pharmacy.
Prescription Serial Number: The unique prescription identifier generated by the pharmacy's data system.
Patient Full Name: Name of the patient for whom the drug is prescribed. (If prescribed for an animal, the label must state the owner's full name and the animal species, e.g., "John Smith (Canine)" ).
Prescribing Practitioner Name: Full name of the practitioner who issued the order.
Drug Name and Manufacturer: The trade/brand name of the drug, OR if a generic drug is dispensed, the generic chemical name PLUS the name of the manufacturer or distributor (e.g., "Amoxicillin 500mg (Mfg: Teva)" ).
Medication Strength and Quantity: Exact dosage strength and total count or volume dispensed.
Directions for Use: Explicit, clear instructions for administration as written by the prescriber (e.g., "Take 1 tablet by mouth twice daily with meals" ). Vague directions such as "Use as directed" are non-compliant unless specifically authorized for complex dosing regimens.
Date of Dispensing: The exact date on which the prescription was filled or refilled.
Expiration or beyond-use date , which may not extend past the manufacturer's expiration date for the product dispensed.
Cautionary Statements: Any required auxiliary warning statements (e.g., "May cause drowsiness" , "Avoid alcohol" , "Take with food" ).
Schedule II–IV federal transfer warning (see below).
Interchange entry. Where an interchange has been made, M.G.L. c. 112, § 12D requires the label to show "Interchange (name of exact drug product dispensed)" . This is a Massachusetts requirement with no federal counterpart, and it pairs with the duty in 247 CMR 9.04 to record the NDC of the product actually dispensed .
Important
Verify the exact statutory list before the exam. Read M.G.L. c. 94C, § 21 and the current 247 CMR 9.00 directly; commercial summaries of the Massachusetts label frequently omit the interchange entry and the animal-species requirement, and occasionally invent a fixed element count.
Schedule II–IV Federal Controlled Substance Transfer Warning
Under federal DEA regulations ( 21 CFR § 290.5 ) and Massachusetts law, all prescription container labels for Schedule II, Schedule III, and Schedule IV controlled substances MUST contain the following verbatim warning statement: "CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed." \text{"CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed."} "CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed."
Important
Schedule V & Schedule VI Exclusion: Federal law does NOT mandate this transfer warning statement on container labels for Schedule V controlled substances or Schedule VI (non-controlled legend) medications. On the MPJE, remember that the transfer warning is legally required ONLY for Schedules II, III, and IV .
FDA Patient Medication Guides (MedGuides)
Patient Medication Guides (MedGuides) are specialized paper handouts mandated by the FDA under 21 CFR Part 208 for specific prescription drugs that pose serious and significant public health concerns.
Mandatory MedGuide Drug Classes
MedGuides are required for drugs where patient decision-making is pivotal or where serious adverse events could be prevented by patient adherence to safety warnings. Representative drug classes include:
NSAIDs (Nonsteroidal Anti-inflammatory Drugs): Risk of severe gastrointestinal bleeding and cardiovascular thrombotic events.
Antidepressants (SSRIs, SNRIs, TCAs): Black box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
Opioid Analgesics & Addiction Treatments: Risk of addiction, abuse, misuse, respiratory depression, and fatal overdose.
Anticoagulants & Antiplatelets (e.g., Warfarin, Rivaroxaban): High risk of major or fatal hemorrhage.
TNF Inhibitors & Biologics: Risk of serious opportunistic infections and malignancies.
Fluoroquinolones: Risk of tendinitis, tendon rupture, and peripheral neuropathy.
Required Dispensing Triggers for MedGuides
Under 21 CFR § 208.24, an outpatient pharmacy MUST provide a MedGuide to the patient or agent whenever the drug is dispensed under any of the following circumstances:
Every Outpatient Fill: Provided with EVERY new prescription AND EVERY refill dispensed in an outpatient setting.
Patient/Caregiver Request: Provided whenever a patient or caregiver requests a copy.
First-Time Institutional Administration: Provided the first time a drug is dispensed in an outpatient clinic or infusion center setting where a healthcare professional will administer it.
Updated MedGuide Content: Provided whenever the FDA mandates a material safety revision to the MedGuide.
REMS Mandate: Provided when required as part of an FDA-approved Risk Evaluation and Mitigation Strategy (REMS).
Patient Package Inserts (PPIs)
Patient Package Inserts (PPIs) are FDA-approved written patient informational materials required specifically for Oral Contraceptives and Estrogen-Containing Products (under 21 CFR § 310.501 and 21 CFR § 310.515 ).
PPI Distribution Requirements: Outpatient vs. Institutional Settings
Setting PPI Dispensing Requirement & Timing Consequences of Non-Compliance
Outpatient / Retail Pharmacy Must be provided with EVERY SINGLE DISPENSING (initial fill AND all refills). Dispensing without a PPI constitutes statutory MISBRANDING under the FDCA.
Institutional Setting ; (Hospital, LTCF, Nursing Home) Must be provided to the patient prior to the administration of the FIRST dose , and subsequently once every 30 days thereafter as long as therapy continues. Failure to provide initial or 30-day PPI constitutes statutory MISBRANDING .
Comparison: MedGuides vs. Patient Package Inserts (PPIs)
Feature Patient Medication Guides (MedGuides) Patient Package Inserts (PPIs)
Targeted Medications High-risk drugs with severe safety concerns (NSAIDs, Opioids, SSRIs, Anticoagulants) Oral Contraceptive drugs and Estrogen-containing medications
Governing Regulation 21 CFR Part 208 21 CFR § 310.501 & § 310.515
Outpatient Frequency Provided with EVERY fill (new scripts AND refills) Provided with EVERY fill (new scripts AND refills)
Institutional Frequency Exempt in inpatient hospital unless requested by patient Prior to 1st dose , then every 30 days thereafter